Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Receives $15.40 Consensus Target Price from Analysts

Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) has been assigned a consensus recommendation of “Buy” from the seven analysts that are covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $15.40.

A number of research analysts recently issued reports on the stock. ValuEngine upgraded shares of Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Zacks Investment Research upgraded shares of Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 22nd. Bank of America restated a “buy” rating and set a $11.00 price objective on shares of Foamix Pharmaceuticals in a report on Friday, August 9th. Cowen set a $30.00 price objective on shares of Foamix Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, September 23rd. Finally, HC Wainwright restated a “buy” rating and set a $11.00 price objective (up previously from $10.00) on shares of Foamix Pharmaceuticals in a report on Monday, October 21st.

Shares of Foamix Pharmaceuticals stock traded up $0.01 during trading on Monday, reaching $2.81. 964,300 shares of the company traded hands, compared to its average volume of 589,201. Foamix Pharmaceuticals has a 1-year low of $1.97 and a 1-year high of $5.08. The company has a 50 day moving average price of $3.10 and a 200-day moving average price of $2.84. The firm has a market capitalization of $168.37 million, a PE ratio of -1.65 and a beta of 1.54.

Foamix Pharmaceuticals (NASDAQ:FOMX) last released its earnings results on Wednesday, August 7th. The specialty pharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.07). Foamix Pharmaceuticals had a negative net margin of 2,115.11% and a negative return on equity of 75.99%. As a group, equities research analysts forecast that Foamix Pharmaceuticals will post -1.64 earnings per share for the current year.

In other Foamix Pharmaceuticals news, CFO Ilan Hadar sold 9,420 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $3.50, for a total transaction of $32,970.00. Following the transaction, the chief financial officer now owns 123,671 shares in the company, valued at $432,848.50. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 2.95% of the company’s stock.

Several hedge funds have recently made changes to their positions in FOMX. ARK Investment Management LLC raised its holdings in shares of Foamix Pharmaceuticals by 25.0% in the second quarter. ARK Investment Management LLC now owns 146,745 shares of the specialty pharmaceutical company’s stock valued at $349,000 after purchasing an additional 29,378 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Foamix Pharmaceuticals by 24.3% in the second quarter. JPMorgan Chase & Co. now owns 112,536 shares of the specialty pharmaceutical company’s stock valued at $270,000 after purchasing an additional 22,027 shares during the last quarter. Delek Group Ltd. raised its holdings in shares of Foamix Pharmaceuticals by 23.2% in the second quarter. Delek Group Ltd. now owns 62,437 shares of the specialty pharmaceutical company’s stock valued at $145,000 after purchasing an additional 11,741 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Foamix Pharmaceuticals by 1,759.8% in the second quarter. Renaissance Technologies LLC now owns 323,600 shares of the specialty pharmaceutical company’s stock valued at $770,000 after purchasing an additional 306,200 shares during the last quarter. Finally, Sofinnova Investments Inc. raised its holdings in shares of Foamix Pharmaceuticals by 34.1% in the second quarter. Sofinnova Investments Inc. now owns 1,115,810 shares of the specialty pharmaceutical company’s stock valued at $2,655,000 after purchasing an additional 283,517 shares during the last quarter. Institutional investors own 47.33% of the company’s stock.

Foamix Pharmaceuticals Company Profile

Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea.

Featured Article: What is the return on assets (ROA) ratio?

Analyst Recommendations for Foamix Pharmaceuticals (NASDAQ:FOMX)

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.